Citigroup Lowers Allergan (AGN) Price Target to $215.00

Allergan (NYSE:AGN) had its price objective decreased by stock analysts at Citigroup to $215.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 26.06% from the company’s current price.

A number of other brokerages have also recently issued reports on AGN. Wells Fargo & Co reaffirmed an “outperform” rating on shares of Allergan in a research note on Monday, September 11th. Deutsche Bank reaffirmed a “buy” rating and set a $262.00 price objective on shares of Allergan in a research note on Tuesday, September 12th. Morgan Stanley cut Allergan from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $284.00 to $228.00 in a research note on Wednesday, September 20th. Cantor Fitzgerald reissued a “hold” rating and issued a $231.00 target price on shares of Allergan in a research note on Friday, September 22nd. Finally, Piper Jaffray Companies set a $227.00 target price on Allergan and gave the stock a “hold” rating in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $229.60.

Shares of Allergan (AGN) opened at $170.56 on Tuesday. Allergan has a 12-month low of $160.07 and a 12-month high of $256.80. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The firm has a market capitalization of $57,300.00, a PE ratio of -7.55, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11.

Allergan (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $4.04 billion. During the same period last year, the firm earned $3.32 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. equities research analysts forecast that Allergan will post 16.27 EPS for the current fiscal year.

Allergan declared that its board has initiated a stock buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

In other news, Chairman Brent L. Saunders acquired 4,600 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The stock was bought at an average cost of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders have bought 17,630 shares of company stock valued at $2,890,057 over the last quarter. Company insiders own 0.36% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Confluence Investment Management LLC grew its position in Allergan by 6.7% in the 4th quarter. Confluence Investment Management LLC now owns 340,131 shares of the company’s stock worth $55,639,000 after purchasing an additional 21,245 shares during the period. Abner Herrman & Brock LLC grew its position in Allergan by 16.6% in the 4th quarter. Abner Herrman & Brock LLC now owns 4,275 shares of the company’s stock worth $699,000 after purchasing an additional 608 shares during the period. Prudential Financial Inc. grew its position in Allergan by 1.1% in the 3rd quarter. Prudential Financial Inc. now owns 1,366,552 shares of the company’s stock worth $280,075,000 after purchasing an additional 14,440 shares during the period. Atlantic Trust Group LLC grew its position in Allergan by 8.2% in the 3rd quarter. Atlantic Trust Group LLC now owns 702,369 shares of the company’s stock worth $143,950,000 after purchasing an additional 53,079 shares during the period. Finally, AXA grew its position in Allergan by 22.4% in the 3rd quarter. AXA now owns 488,257 shares of the company’s stock worth $100,068,000 after purchasing an additional 89,257 shares during the period. Institutional investors own 81.14% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/09/citigroup-lowers-allergan-agn-price-target-to-215-00.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

The Fly

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit